CAMBRIDGE, Mass. - Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company focused on brain health treatments, is scheduled to host a live webcast to discuss its fourth quarter and full year 2023 financial results on February 14, 2024. The event will take place at 8:00 a.m. Eastern Time.
The webcast will be accessible to the public through the Investor Relations section of the company's website. Following the live broadcast, a replay will be available for up to 30 days for those unable to attend the original airing.
Founded in 2010 and with headquarters in Cambridge, Massachusetts, Sage Therapeutics has been at the forefront of developing treatments for brain health issues. The company's portfolio includes two FDA-approved medications for postpartum depression, and it continues to work on a pipeline of potential therapies aimed at addressing unmet needs in the realm of brain health.
This announcement comes as the company seeks to communicate its financial health and business trajectory to investors and stakeholders. The webcast is anticipated to provide insight into the company's performance over the past quarter and year, as well as updates on its business operations.
Details of the webcast will be made available on the company's website, and interested parties are encouraged to visit the site to gain access to the broadcast. The information discussed in the webcast is based on a press release statement issued by Sage Therapeutics.
InvestingPro Insights
In preparation for Sage Therapeutics' upcoming webcast discussing their financial results, current and potential investors might find the following InvestingPro Insights particularly informative. According to real-time data from InvestingPro, Sage Therapeutics holds a market capitalization of $1.56B. The company has experienced a substantial revenue growth of 75.58% over the last twelve months as of Q1 2023, which is a positive signal for sales dynamics. However, the company's gross profit margin during the same period stands at a concerning -3272.24%, reflecting the challenges in translating sales into net income.
InvestingPro Tips suggest that Sage Therapeutics has more cash than debt on its balance sheet, indicating a solid liquidity position. This is further supported by the fact that the company's liquid assets exceed its short-term obligations. On the upside, analysts anticipate sales growth in the current year, which could be an encouraging sign for future revenue streams. Nevertheless, it is important to note that analysts do not expect the company to be profitable this year, and Sage has not been profitable over the last twelve months.
For those looking to delve deeper into Sage Therapeutics' financials and future prospects, InvestingPro offers additional insights. Currently, there are over 10 additional InvestingPro Tips available for Sage Therapeutics, accessible through an InvestingPro+ subscription. The InvestingPro subscription is now on a special New Year sale with a discount of up to 50%. To further sweeten the deal, use coupon code SFY24 to get an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 to get an additional 10% off a 1-year InvestingPro+ subscription. These tips could provide valuable context for the upcoming webcast and help investors make more informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.